INMB
INmune Bio, Inc. NASDAQ Listed Feb 4, 2019$1.46
Mkt Cap $38.8M
52w Low $1.09
3.5% of range
52w High $11.64
50d MA $1.32
200d MA $1.75
P/E (TTM)
-0.8x
EV/EBITDA
-0.6x
P/B
1.7x
Debt/Equity
0.0x
ROE
-195.3%
P/FCF
-1.8x
RSI (14)
—
ATR (14)
—
Beta
0.89
50d MA
$1.32
200d MA
$1.75
Avg Volume
414.5K
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
225 NE Mizner Boulevard · Boca Raton, FL 33432 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -0.27 | -0.18 | +33.3% | 1.14 | -2.6% | -0.9% | +7.9% | +6.1% | +7.9% | +11.4% | — |
| Oct 30, 2025 | AMC | -0.31 | -0.24 | +22.6% | 1.73 | +1.2% | +5.8% | +4.0% | -0.6% | +2.3% | -5.8% | — |
| Aug 7, 2025 | AMC | -0.37 | -0.34 | +8.1% | 2.79 | -13.3% | -8.2% | -14.0% | -13.3% | -8.2% | -12.2% | — |
| May 8, 2025 | AMC | -0.43 | -0.43 | +0.0% | 7.09 | +9.6% | -1.7% | +7.8% | +13.7% | +4.8% | +2.8% | — |
| Mar 27, 2025 | AMC | -0.54 | -0.40 | +25.9% | 7.41 | +1.9% | +1.5% | +5.4% | +2.4% | +8.9% | +4.9% | — |
| Oct 31, 2024 | AMC | -0.49 | -0.60 | -22.4% | 5.85 | +1.5% | +3.2% | +6.8% | +5.8% | +9.9% | +6.3% | — |
| Aug 1, 2024 | AMC | -0.63 | -0.50 | +20.6% | 7.91 | -2.0% | +3.3% | -3.4% | -9.4% | -10.9% | -4.0% | — |
| May 9, 2024 | AMC | -0.53 | -0.61 | -15.1% | 10.77 | -0.9% | -7.0% | -7.9% | -2.6% | +5.5% | +3.7% | — |
| Mar 28, 2024 | AMC | -0.44 | -0.47 | -6.8% | 11.75 | +0.0% | -2.0% | -6.8% | -14.0% | -12.8% | -12.0% | — |
| Nov 1, 2023 | AMC | -0.39 | -0.48 | -23.1% | 7.07 | -2.1% | -3.8% | +2.1% | +2.8% | +0.8% | +3.0% | — |
| Aug 7, 2023 | AMC | -0.40 | -0.36 | +10.0% | 8.76 | -4.7% | -10.4% | -2.7% | -4.1% | -5.0% | -6.3% | — |
| May 3, 2023 | AMC | -0.02 | -0.36 | -1700.0% | 7.25 | +1.4% | +4.3% | +11.2% | +15.4% | +16.6% | +20.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11 | LUCID CAPITAL MARKETS | Upgrade | Neutral → Buy | — | $1.28 | $1.38 | +7.8% | +10.9% | +3.9% | +2.3% | +5.5% | +0.0% |
| Jul 2 | Maxim Group | Maintains | Buy → Buy | — | $2.09 | $2.07 | -1.0% | +12.9% | +21.1% | +10.0% | +10.0% | +12.9% |
| Jul 1 | Scotiabank | Downgrade | Sector Outperform → Sector Underperform | — | $2.31 | $2.09 | -9.5% | -9.5% | +2.2% | +9.5% | -0.4% | -0.4% |
| Jul 1 | BTIG | Downgrade | Buy → Neutral | — | $2.31 | $2.09 | -9.5% | -9.5% | +2.2% | +9.5% | -0.4% | -0.4% |
| Feb 13 | Maxim Group | Maintains | Buy → Buy | — | $9.13 | $9.40 | +3.0% | +1.9% | +0.5% | +0.5% | +3.9% | -0.4% |
| Feb 11 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $9.12 | $9.20 | +0.9% | -9.5% | +0.1% | +2.0% | +0.7% | +0.7% |
| Jun 1 | Baird | Maintains | Outperform → Outperform | — | $7.58 | $7.98 | +5.3% | +3.4% | +3.7% | +10.2% | +10.6% | +8.8% |
| May 24 | B. Riley Securities | Downgrade | Buy → Neutral | — | $7.27 | $4.79 | -34.1% | -24.6% | -15.1% | -12.9% | -6.5% | -5.1% |
| May 24 | BTIG | Maintains | Buy → Buy | — | $7.27 | $4.79 | -34.1% | -24.6% | -15.1% | -12.9% | -6.5% | -5.1% |
| Jan 24 | B. Riley Securities | Maintains | Buy → Buy | — | $8.78 | $8.33 | -5.1% | +0.8% | +2.5% | -0.7% | -5.5% | +1.1% |
| Apr 21 | B. Riley Securities | Maintains | Buy → Buy | — | $11.02 | $11.49 | +4.3% | +18.2% | +12.4% | +8.4% | +7.8% | +7.7% |
| Apr 21 | B. Riley FBR | Maintains | Buy → Buy | — | $11.02 | $11.49 | +4.3% | +18.2% | +12.4% | +8.4% | +7.8% | +7.7% |
| Nov 25 | H.C. Wainwright | Maintains | Buy → Buy | — | $8.47 | $8.49 | +0.2% | +0.0% | +5.2% | +4.8% | +1.9% | +1.5% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.47 | $8.49 | +0.2% | +0.0% | +5.2% | +4.8% | +1.9% | +1.5% |
| Nov 25 | BTIG | Maintains | Buy → Buy | — | $8.47 | $8.49 | +0.2% | +0.0% | +5.2% | +4.8% | +1.9% | +1.5% |
| Nov 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.69 | $7.99 | +3.9% | +0.7% | +6.6% | +8.2% | +11.4% | +13.3% |
| Sep 1 | BTIG | Maintains | Buy → Buy | — | $10.50 | $10.91 | +3.9% | -1.1% | -6.9% | -10.1% | -11.3% | -11.1% |
| Jul 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.75 | $15.00 | -4.8% | -17.1% | -31.9% | -29.2% | -10.6% | -14.4% |
| May 15 | H.C. Wainwright | Maintains | Buy → Buy | — | $5.36 | $5.21 | -2.8% | +2.8% | +3.4% | +7.6% | +13.6% | +10.1% |
| Mar 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.80 | $4.01 | -16.5% | -29.8% | -35.4% | -42.9% | -40.0% | -54.0% |
| Mar 12 | H.C. Wainwright | Maintains | Buy → Buy | — | $4.80 | $4.01 | -16.5% | -29.8% | -35.4% | -42.9% | -40.0% | -54.0% |
| Mar 19 | Maxim Group | Maintains | Buy → Buy | — | $7.73 | $7.66 | -0.9% | +2.8% | +2.3% | +2.5% | +3.4% | +5.0% |
No insider trades available.
8-K · 7.01
! Medium
INmune Bio Inc. -- 8-K 7.01: Regulation FD Disclosure
INmune Bio furnished a presentation as part of its regulatory disclosure, likely providing updates on company operations or strategic initiatives to investors and the market.
Feb 27
8-K · 8.01
!! High
INmune Bio Inc. -- 8-K 8.01: Material Event / Announcement
INmune Bio disclosed material information via press release but the 8-K filing does not specify the announcement details, requiring investors to review the attached exhibit for complete disclosure.
Feb 23
8-K · 8.01
!! High
INmune Bio Inc. -- 8-K 8.01: Material Event / Announcement
INmune Bio disclosed material information via press release but the filing provides no substantive details about the announcement's content or financial impact on the company.
Feb 19
8-K · 7.01
! Medium
INmune Bio Inc. -- 8-K 7.01: Regulation FD Disclosure
INmune Bio received FDA confirmation of its End-of-Phase 2 meeting minutes, potentially clarifying regulatory pathway requirements for advancing its clinical development program.
Feb 13
Data updated apr 25, 2026 3:40pm
· Source: massive.com